[e-drug] Organizations contest the constitutionality of the Brazilian IP Law

E-DRUG: Organizations contest the constitutionality of the Brazilian IP Law
----------------------------------------------------

Mechanism for the granting of patents known as "pipeline" patents violates
the Federal Constitution

On November 28th, the National Federation of Pharmacists (FENAFAR), on behalf of the Brazilian Network for the Integration of Peoples (Rebrip), presented to the General Attorney of the Republic, Mr. Antônio Fernando Barros e Silva e Souza, evidence that demonstrates the nconstitutionality of two articles of the Brazilian Industrial Property Law (Law 9.279/96). According to the authors of the case, articles 230 and 231 of Law n^o. 9.279, that created the patent granting mechanism known as the "pipeline", violate the constitutional principles that impose the supremacy of society's interest and the pursuit of the country's technological and economic development over intellectual property protections (art. 5, XIX). They argue that the granting of pipeline patents also violates the society's acquired right (art. 5, XXXVI); implied due legal process (art. 5, LIV) and the principle of equal treatment before the law (art. 5, caput).

   The pipeline mechanism is an institution created by the Industrial
   Property Law that allowed the filling of patents in technological
   fields that, prior to 1996, had not yet been granted in Brazil. The
   mechanism made it possible to obtain patent protections for
   pharmaceutical and food products (among other products). The requests
   for patents via the pipeline mechanism are only subject to a formal
   analysis and they follow the terms of the patent granted in foreign
   countries. They are not submitted to a technical evaluation of the
   product's ability to meet patentability requirements - novelty,
   inventiveness and industrial application - conducted by the Brazilian
   patent office, the National Institute of Industrial Property (INPI in
   Portuguese). In total, 1 182 patents were filed under the pipeline
   mechanism, many of which are for essential medicines used in the
   treatment of HIV/AIDS and leukemia, for example. Many of the products
   for which patents had been granted through this mechanism were already
   in public domain prior to 1996.

   A study elaborated by economists calculated the hypothetical financial
   losses caused by the adoption of the pipeline mechanism in the case of
   government purchases of five anti-retroviral drugs (ARVs), during the
   period 2001-2007. The results show that, due to the granting of
   unmerited patent protections for these medicines, the Brazilian state
   paid an additional US$ 420 million, when prices paid were compared to
   the World Health Organisation's minimum prices, and an extra US$ 519
   million, when compared to the minimum prices of Doctors Without
   Borders (MSF) for the ARVs.

    In the opinion of Cristina Pimenta, General Coordinator of the
   Brazilian Interdisciplinary AIDS Organisation (ABIA), the organisation
   currently coordinating the Rebrip's Working Group on Intellectual
   Property, "instead of contributing to the development of the country
   and serving public interest, the pipeline mechanism only serves as an
   obstacle to universal access and gratuity of treatment for people with
   HIV/AIDS". FENAFAR's president, Célia Chaves, adds, "no gain has been
   made by this concession - neither for the national pharmaceutical
   industry and sector, nor for the population in general. All were
   harmed by pipeline patents".

   Rebrip and FENAFAR hope to have the current case approved by the
   General Attorney of the Republic, so that it will be sent to the
   Federal Supreme Court in the form of a direct action of
   unconstitutionality.

   Examples of pipeline patents:

   Efavirenz, a medicine for which a compulsory license was recently
   issued, is protected by a patent granted through the pipeline
   mechanism. In other words, when the patent of this drug was filed in
   Brazil, it no longer met the novelty requirement, as the information
   on the invention had already been published abroad five years earlier.
   This active ingredient could have been produced in Brazil, as it was
   in India.

   Other medicines that are fundamental for curbing the HIV/AIDS
   epidemic, such as lopinavir/ritonavir, abacavir, nelfinavir and
   amprenavir, also were protected by the pipeline mechanism, and as
   such, were withdrawn from public domain without any evaluation of its
   importance in terms of the country's interests. Furthermore, the
   medicine for cancer - imatinib or Glivec (brand name) - was also
   protected by the pipeline mechanism. This drug, used to treat people
   living with Chronic Myeloid Leukemia, currently costs R$ 10 000,000
   (ten thousand Brasilian reals) per month, per patient.

Gabriela Chaves
gabriela@abiaids.org.br